Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial.
By M. Bafadhel, S. Mckenna, S. Terry, V. Mistry, M. Pancholi, P. Venge, D. Lomas, M. Barer, S. Johnston, I. Pavord and 1 more. American Journal of Respiratory and Critical Care Medicine, 2012
612 citations recorded by the source corpus.
Subfields: Physiology, Pulmonary and Respiratory Medicine, Sociology and Political Science
View Paper: https://www.semanticscholar.org/paper/4064e81092acf541c0694a2f8524b6b6a11dd61b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Physiology
In Pulmonary and Respiratory Medicine
- J. Wedzicha
- Jorgen Vestbo
- A. Anzueto
- Bartolome Celli
- R. Rodríguez-Roisín
- R. Stockley
- D. Parums
- P. Barnes
In Sociology and Political Science
Citations in the corpus
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019 (2019, background): “A clinical trial reported that blood eosinophil counts may predict which patients receive benefit from oral corticosteroid treatment during exacerbations (39).”
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. (2017, background): “Glucocorticoids may be less efficacious to treat exacerbations in patients with lower blood eosinophil levels.(59,243,271)”
- Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary (2023, positive): “Recent studies suggest that glucocorticoids may be less efficacious to treat COPD exacerbations in patients with lower blood eosinophil levels (133).”